Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
110.20    1.60 (1.47%)
Bid:
110.20
Ask:
111.80
Spread: 1.60 (1.452%)
Market Cap: £180.67m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Trading Statement - Spring 2025

1 May 2025 07:00

RNS Number : 9319G
Synthomer PLC
01 May 2025
 

Synthomer plcSpring 2025 trading statement

Q1 EBITDA ahead of prior year driven by self-help initiatives

 

Synthomer plc ('Synthomer' or the 'Group') today issues a scheduled update on trading for the first quarter of 2025, ahead of today's Annual General Meeting (AGM). Results of voting at the AGM will be announced later today.

 

· Q1 2025 Continuing Group EBITDA and margin ahead of Q1 2024

· Constant currency revenue growth and margin progress in AS and HPPM, partially offset by slower CCS markets, predominantly in energy solutions and the USA

· Focused on delivering further cost and cash self-help programmes and strategic transformation objectives

· 'In region for region' manufacturing strategy provides resilience in a more protectionist market environment, with limited direct impact of tariffs anticipated

· No change to our previously stated expectation of further earnings progress in 2025, recognising that end-market demand uncertainty increases in the event of a sustained period of elevated trade tensions

 

Continuing Group EBITDA and EBITDA margin increased in the first quarter of 2025, despite modestly lower volumes relative to the strong first quarter of the prior year, which benefited from the disruption to supply chains into Europe via the Red Sea and significant customer restocking. Our Adhesive Solutions (AS) and Health & Protection and Performance Materials (HPPM) divisions both delivered increased gross margin and EBITDA, principally through a further improvement in product and geographical mix and self-help cost efficiency programmes. In the Coatings & Construction Solutions (CCS) division, delayed energy orders and moderating end-market activity in the USA were only partially offset by improved construction activity in Europe. Robust pricing continued to be achieved across the Group, recognising lower energy and raw materials costs in the period.

 

We have made further progress in delivering our speciality solutions strategy, alongside our sustained focus on generating cash flow and reducing leverage. New speciality investments in the USA and the Middle East came onstream in the period and are immediately profit and cash accretive. We continue to progress the formal divestment processes for non-core businesses in Europe.

 

Our strategy of manufacturing close to our customers globally substantially mitigates our direct exposure to recent tariff announcements, which we are looking to offset through price. Our Health & Protection customers that are based in Malaysia are in a strong position to benefit relative to their China-based competitors as a result of the tariff changes. At the same time, geopolitical tensions have made end-market demand more unpredictable, particularly in the USA, which represents around 25% of our revenues. Notwithstanding this increased uncertainty, at this stage we continue to expect further earnings progress and positive Free Cash Flow in 2025, driven primarily by accelerating self-help benefits and delivery of our strategic plans.

 

Commenting, Synthomer CEO Michael Willome said:

"We delivered earnings growth in Q1 2025 against difficult market trends and a strong first quarter last year, largely through our relentless focus on our customers, costs and cash. Our 'in region for region' manufacturing strategy means we are in a robust position to weather a more protectionist trade environment. Alongside our ongoing prioritisation of deleveraging, we continue to rigorously allocate our resources to key growth opportunities across our global business. Although our end-markets face increasing macroeconomic and geopolitical uncertainty, our strategic transformation continues to enhance our ability to convert customer demand for our products into substantially greater profitability and returns."

 

 

Further information:

Investors: Faisal Tabbah, Vice President Investor Relations

Tel: +44 (0) 1279 775 306

Media: Nick Hasell, FTI Consulting

Tel: +44 (0) 203 727 1340

 

Notes

Synthomer plans to report interim results on 5 August 2025. Legal Entity Identifier (LEI): 213800EHT3TI1KPQQJ56. Classification as per DTR 6 Annex 1R: 3.1.

 

Synthomer plc is a leading supplier of high-performance, highly specialised polymers and ingredients that play vital roles in key sectors such as coatings, construction, adhesives, and health and protection - growing markets for customers who serve billions of end users worldwide. Headquartered in London, UK and listed there since 1971, we employ c.4,000 employees across our five innovation centres of excellence and 31 manufacturing sites across Europe, North America, Middle East and Asia. With more than 6,000 blue-chip customers and £2.0bn in continuing revenue in 2024, our business is built around three divisions, serving customers in attractive end markets where demand is driven by global megatrends including urbanisation, demographic change, climate change and sustainability, and shifting economic power. In Coatings & Construction Solutions, our specialist polymers enhance the sustainability and performance of a wide range of coatings and construction products. We serve customers in applications including architectural and masonry coatings, mortar modification, waterproofing and flooring, fibre bonding, and energy solutions. In Adhesive Solutions our products help our customers bond, modify and compatibilise surfaces and components for applications including tapes and labels, packaging, hygiene, tyres and plastic modification, improving permeability, strength, elasticity, damping, dispersion and grip. In Health & Protection and Performance Materials we are a world-leading supplier of water-based polymers for medical gloves, and a major European manufacturer of high-performance binders, foams and other products serving customers in a range of end markets. Our purpose is creating innovative and sustainable solutions for the benefit of customers and society. Around 20% of our sales volumes are from new and patent protected products. At our innovation centres of excellence in the UK, China, Germany, Malaysia and Ohio, USA we collaborate closely with our customers to develop new products and enhance existing ones tailored to their needs, with an increasing range of sustainability benefits. Our 2030 decarbonisation targets have been approved by the Science Based Targets initiative as being in line with what the latest climate science says is necessary to meet the goals of the Paris Agreement, and since 2021 we have held the London Stock Exchange Green Economy Mark, which recognises green technology businesses making a significant contribution to a more sustainable, low-carbon economy. Find us at www.synthomer.com or search for Synthomer on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFETSRIIVIE
Date   Source Headline
13th Jul 201210:38 amRNSChange of Auditor
6th Jul 20129:38 amRNSHolding(s) in Company
3rd Jul 20124:35 pmRNSHolding(s) in Company
2nd Jul 201212:46 pmRNSHolding(s) in Company
2nd Jul 201211:11 amRNSDirector/PDMR Shareholding
27th Jun 20127:00 amRNSTrading Statement
12th Jun 201210:30 amRNSDirector/PDMR Shareholding
8th Jun 20122:09 pmRNSDirector/PDMR Shareholding
7th Jun 20124:35 pmRNSDirector/PDMR Shareholding
25th May 201211:00 amRNSDirector Declaration
17th May 201212:22 pmRNSResult of AGM
17th May 201211:00 amRNSDirectorate Change
17th May 20127:00 amRNSInterim Management Statement
14th May 20123:47 pmRNSAnnual Information Update
17th Apr 20129:18 amRNSAnnual Financial Report
3rd Apr 20123:11 pmRNSDirector/PDMR Shareholding
2nd Apr 20127:00 amRNSMarl Site Operations
28th Mar 20125:15 pmRNSHolding(s) in Company
26th Mar 20127:00 amRNSDirector/PDMR Shareholding
23rd Mar 20127:00 amRNSDirectorate Change
19th Mar 20124:10 pmRNSDirector/PDMR Shareholding
16th Mar 20121:48 pmRNSDirector/PDMR Shareholding
16th Mar 20121:46 pmRNSDirector/PDMR Shareholding
16th Mar 20121:09 pmRNSDirector/PDMR Shareholding
14th Mar 20123:52 pmRNSDirector/PDMR Shareholding
14th Mar 20127:00 amRNSFinal Results
11th Jan 20127:00 amRNSTrading Update
9th Jan 201210:24 amRNSDirector/PDMR Shareholding
3rd Jan 20124:51 pmRNSDirector/PDMR Shareholding
1st Dec 20117:00 amRNSDisposal of Pharma Division
25th Nov 20117:00 amRNSDirectorate Change
10th Nov 20117:00 amRNSInterim Management Statement
1st Nov 20113:33 pmRNSHolding(s) in Company
31st Oct 201110:15 amRNSHolding(s) in Company
20th Oct 20112:42 pmRNSHolding(s) in Company
17th Oct 20118:20 amRNSAcquisition
28th Sep 20117:00 amRNSAnalyst and Investor Site Visit
5th Sep 20117:00 amRNSAppointment of Joint Broker
26th Aug 20117:00 amRNSHalf Yearly Report
10th Aug 20118:58 amRNSHolding(s) in Company
4th Aug 20119:02 amRNSBoard appointment
27th Jul 20111:12 pmRNSHolding(s) in Company
29th Jun 20114:46 pmRNSDirector/PDMR Shareholding
29th Jun 20114:44 pmRNSDirector/PDMR Shareholding
29th Jun 20112:17 pmRNSResult of EGM
22nd Jun 20113:59 pmRNSHolding(s) in Company
16th Jun 20114:39 pmRNSHolding(s) in Company
16th Jun 20114:37 pmRNSHolding(s) in Company
13th Jun 201111:14 amRNSNotice of EGM
9th Jun 201110:44 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.